A method to image muscarinic acetylcholine receptors (muscarinic receptors) noninvasively in human brain in vivo was developed using [123I]4-iododexetimide ([123I]IDex), [123I]4-iodolevetimide ([,23I]ILev), and sin gle photon emission computed tomography (SPECT).
ately after the injection peak in all brain regions and did not correspond to muscarinic receptor concentrations.
[123I]IDex activity in neocortex and neostriatum during equilibrium was six to seven times higher than [123I]ILev activity. The data demonstrate that [1231] IDex binds spe cifically to muscarinic receptors in vivo, whereas [1231] _ ILev represents the nonspecific part of [1231]IDex bind ing. Subtraction of [1231] ILev from [1231] IDex images on a pixel-by-pixel basis therefore reflects specific [1231]IDex binding to muscarinic receptors. Owing to its high spe cific binding, [123I1IDex has the potential to measure small changes in muscarinic receptor characteristics in vivo with SPECT. The use of stereoisomerism directly to measure nonspecific binding of [123I]IDex in vivo may reduce complexity in modeling approaches to muscarinic acetylcholine receptors in human brain. Key Words: Cholinergic system-Muscarinic acetylcholine recep tor-Single photon emission computed tomography.
learning (Sitaram et aI., 1978; Coyle et aI., 1983) . Changes in muscarinic receptor number have been demonstrated in epileptogenic foci in animals (Mc Namara, 1978) . The involvement of muscarinic re ceptors in diseases of the human brain such as Alz heimer's, Huntington's, and Parkinson's diseases has been suggested by postmortem studies (Pala cios et aI., 1990) .
Previous in vivo studies of muscarinic recep tors in human brain used 3-quinuclidinyl-4-[123I]iodobenzilate (Holman et aI., 1985; Wein berger et aI., 1989) , [N-llC-methyl]benztropine (Dewey et aI., 1990) , [llC] scopolamine (Koeppe et aI., 1986 (Koeppe et aI., , 1987 Frey et aI., 1987) , and [llC]tropanyl benzilate (Lee et aI., 1991) . The present study em ploys e23I]4-iododexetimide ([1 2 3I]lDex) and e 2 31]4-iodolevetimide ([1231]ILev) . Dexetimide is a high-affinity muscarinic receptor antagonist with an in vitro half-life of dissociation from muscarinic re ceptors of 2. 3 min (Laduron et aI. , 1978) , and le vetimide is its pharmacologically inactive enantio mer. This two-ligand approach offers potential ad vantages over previous in vivo strategies. First, since the physical half-life of 1 2 31 is relatively long (13. 3 h), the use of [1 2 31]IDex may permit prolonged data acquisition and extensive tracer clearance from nonspecific compartments. Second, the use of [1 2 31]ILev should permit measurement of brain non specific binding of [1 2 3I]IDex in vivo (Laduron et aI. , 1978) . Nonspecific binding in vivo has recently been investigated in rat brain with [12 5 1]3 _ quinuclidinyl-4-iodobenzilate (Sawada et aI. , 1990 ), but has not been directly measured in humans. We therefore developed a method to image muscarinic receptors in vivo using [1 2 3I]IDex and its pharma cologically inactive enantiomer, [1 2 31]ILev. The synthesis of the ligands and their biological evalua tion in animals have been reported previously (Wil son et aI. , 1989) .
MATERIALS AND METHODS

Subject selection and preparation
Four healthy men (aged 25-36 years), recruited through advertisement, were studied. They gave no history of neurological or psychiatric illnesses or drug treatment. Their mean body weight was 165 ± 35 lbs. All subjects provided informed consent in compliance with the Joint Committee on Clinical Investigation of the Johns Hopkins Medical Institutions. Paired [123I]IDex and e23I]ILev studies were obtained in three subjects and performed within 3 weeks of each other. In the fourth subject, only a [123I1IDex study was performed. The dosimetry of [123I]IDex was evaluated in biodistribution studies in mice. The effective dose equivalent calculated for hu mans is 0.072 rem/mCi [123I]IDex, assuming a quality fac tor for gamma radiation of 1. To minimize 1231 uptake into the thyroid gland, subjects were given 1.5 g potassium iodide/day (SSKI, oral solution) from 3 days before to 3 days after tracer injection.
Anatomical localization
x-Ray computed tomography (CT) was performed prior to all SPECT studies. To ensure reproducible positioning of the head between CT and single photon emission CT (SPECT) studies, a tightly fitted thermally molded plastic face mask (Polysplint; Poly-Med Manufacturing, Balti more, MD, U.S.A.) was made for each subject. The mask extended from the upper forehead to the chest and later ally to the ears. Extension of the mask to the chest en abled a continuous monitoring of the head position during SPECT acquisitions using a laser beam mounted outside the SPECT gantry. A trans axial reference plane was cho sen on a CT topogram passing through the center of the thalamus and head of the caudate, parallel to the glabella inion line (CT reference plane). This plane was marked on the face mask with the aid of laser alignment beams. A set of CT images 8 mm apart was then acquired parallel to the CT reference plane.
For SPECT acquisition, subjects were placed supine with the head positioned in a headholder. Room lights were dimmed, and room sounds were kept to a minimum. No specific sensory or cognitive restraints were applied. The SPECT alignment lights were used to indicate the SPECT reference plane on the mask. To determine the angle between CT and SPECT reference planes, three capillary tubes (10 mm long) filled with 50 fLCi 99mTc each were mounted in the CT reference plane. A high resolution SPECT scan was subsequently performed and the angle between the CT and SPECT reference plane determined. This angle was used for subsequent SPECT data reconstructions in free angle reconstruction mode. Thus, the angle and rostrocaudal level of the CT and SPECT reference planes match, allowing direct compar ison of muscarinic receptor binding and anatomy.
Data acquisition
[1231]IDex and e231]ILev were synthesized from the corresponding trimethylsilyl precursors and Na1231 (Nor dion International, Canada) as previously published (Wil son et aI., 1989) . The 127I(p,5n)123Xe � 1231 reaction was used. This reaction produces high-purity 1231 with only a small amount of 1251 that does not contribute to degrada tion of image quality. The specific activity ranged be tween 1,800 and 2,000 mCi/fLmol for [123I]IDex and be tween 300 and 2,000 mCi/fLmol for [123I]ILev, calculated at the time of injection.
A four-detector rotating SPECT camera (Neuro SPECT; Summit Nuclear-Hitachi) was used for data ac quisition. The camera performance has previously been described in detail (Kimura et aI., 1990) . Collimation was performed with a low-energy general-purpose (LEGP) collimator for determining tracer kinetics and a low energy high-resolution (LEHR) collimator for anatomical definition. Septal penetration in both collimators is <1.2% for 1231 (Kimura et aI., 1990) . The energy window was set to 159 keY ± 10%.
The point-spread function of the SPECT device was measured in water at the center of the field of view using a point source (diameter of <1 mm) of 99mTc. Data were sampled at intervals of < 10% of the anticipated full width at half-maximum (FWHM). A Gaussian function was fit ted to the measured data and the FWHM derived. The in-plane resolution was 13.5 and 18 mm and the axial resolution 14 and 21 mm for LEHR and LEGP collima tion, respectively.
SUbjects were administered 5.5-6.8 mCi of [1231]IDex or 2.4-5.7 mCi of [123I]ILev as an intravenous bolus in jection over 20 to 30 s. Each subject underwent a series of 11 SPECT acquisitions using a low-energy collimator (64 projection views per acquisition, 3600 rotation, matrix 64 x 64) from 10 min to 24 h after injection. The acquisition time per projection view was 10 s during the first hour, 20 s during the second hour, and subsequently 30 s. These 11 SPECT acquisitions started at 13, 28, 72, 98, 126, 170, 256, 356, 420, 679 , and 1459 min after injection with slight differences «2 min during the first 3 h, <5 min thereaf ter) between subjects. For optimal anatomical informa-. tion, an additional set of two SPECT acquisitions using the high-resolution collimator (matrix 64 x 64, 64 frames, frame time 55 s, 3600 rotation) was performed between 6 and 8 h after injection. Rest intervals, in which the sub jects could freely move around, were interposed between acquisitions starting later than 1 h post injection. Start time and duration of [123I]IDex and [123I1ILev SPECT scans were precisely matched.
Cerebral blood flow was measured with 99ffiTc-labeled hexamethyl-propyleneamine oxine (HMP AO; Ceretec; Amersham) in one subject. SPECT data acquisition was started 10 min after intravenous injection of 20 mCi HMPAO in high-resolution mode. The acquisition time was 30 min. Head position, SPECT acquisition, and re construction parameters were otherwise identical to those used for the receptor studies, thus allowing direct comparison of blood flow and binding to muscarinic re ceptors. The effective dose equivalent for HMPAO was calculated based on data reported by Amersham for a 70-kg human adult with urination every 2 h. It amounts to 0.043 rem/mCi.
During the SPECT scans, the head position was con stantly monitored and adjusted to maintain accurate po sitioning of the laser light on the SPECT alignment line. Under these conditions, the center of equally sized el lipses drawn visually on the edge of brain tissue was in 70% of the images identical. In 30%, it differed by not more than 4 mm (edge length of 1 pixel) in the x-and y-dimension.
Data analysis
SPECT data were filtered (Butterworth filter, cutoff frequency 0.2 cycle/pixel) and reconstructed (Ramachan dran filter, z-axis dimension 8 mm) in a free angle mode. Attenuation correction was performed using ellipses and Chang's correction method, which assumes that the at tenuation process is homogeneous throughout the brain and can be described by an exponential function. The corresponding coefficient (0.1 cm -I ) was determined us ing a homogeneous head phantom. This coefficient yielded a variance in 25 central and peripheral regions of interest of <2%.
Square regions of interest (12 x 12 mm) were placed on transaxial SPECT images. Basal ganglia, thalamus, and temporoparietal, frontal, and occipital cortex were sam pled on the transaxial SPECT image matching the CT reference plane. The temporal cortex (superior and me dial gyri) was analyzed 16 mm caudal and the cerebellum 32 mm caudal to the CT reference plane. These distances were chosen based on stereotaxic coordinates (Talairach and Tournoux, 1988) , such that the imaging plane passes through the z-axis center of the region of interest. This uniform topographic approach was justified, because dif ferences in brain size and shape between the four indi viduals were minimal: The length of the glabella-inion line was 18.5 ± 0.3 cm (mean ± SD, range 18.1-18.9) and the greatest perpendicular distance from the glabella-inion line to the vertex 9.6 ± 0.3 cm (mean ± SD, range 9.4-9.9) as measured on a lateral x-ray radiograph. The plane passing through the center of the cerebellum was deter mined by using the CT scans. Positioning of regions of interest in cerebellum was determined on the 10-to 20min SPECT scan mainly reflecting blood flow and trans port across the blood-brain barrier. At this time its con tours were clearly delineated. Activity in homologous left and right regions was averaged and decay corrected. SPECT data were calibrated to the well counter used to measure the injected activity.
SPECT data were corrected on a regional basis for the effects of partial volume averaging. The theory and vali dation of this technique have been separately described in J Cereb Blood Flow Metab, Vol. 12, No.4, 1992 detail (MUller-Gartner et aI., 1991a). Briefly, the regional recovery coe(ficient (RC) of a radiotracer was estimated in computer simulations by means of a three-dimensional magnetic resonance imaging (MRI)-based computer generated brain phantom. The phantom reflects the three dimensional configuration of gray matter, white matter, and cerebrospinal fluid as determined by MRI. Voxels representing these compartments were assigned values to reflect the actual muscarinic acetylcholine receptor num ber in a given compartment as known from in vitro auto radiography (Cortes et aI., 1987) . The algorithm allows one to simulate SPECT images for a given subject using a specified SPECT device and a specific tracer. The mean error between signals in an actually acquired image and the corresponding simulated image was <6% in gray mat ter regions (n = 4 experiments).
The mean RC in a given brain structure was determined using phantoms as specified above from three normal controls. These three controls were not identical to the subjects in whom the e23I]lDex SPECT scans were per formed, but were age matched. The RC was estimated by dividing the mean regional activity in the simulated image by the actual concentration in the coded MR images. The mean regional activity as measured in the [123I]IDex SPECT scans was then multiplied by the inverse of the RC to correct for the effects of partial volume averaging. For RC analysis, the same regions of interest were used as described for measuring the [123I]lDex activity in the SPECT scans.
Analysis of brain radioactivity
To evaluate the presence of radioactive metabolites of IDe x in brain tissue, the brain radioactivity after intrave nous injection of IDex was chemically identified in rats. Two male rats (Sprague-Dawley, 300 g), housed on a reg ular 12: 12 light/dark cycle, received a tail vein injection of p25I]IDex (0.5-1 ml, 400-500 f-lCi). The animals were killed 20 min after injection by decapitation. The brains were rapidly removed and homogenized in IO ml of ice cold methanol using a Polytron tissue disrupter (Brink mann, Switzerland). One hundred microliters of a 200 f-lM solution of nonradioactive IDex was added to the ho mogenate. The solution was mixed and centrifuged at 50,000 g for 10 min. The pellet and the supernatant were separated and the respective radioactivity concentrations determined using a gamma counter. Under these circum stances, >93% of the radioactivity was extracted from brain. Five milliliters of the supernatant was then diluted with 5 ml of H 2 0 and passed through activated CIS re verse-phase SEP-PAK columns (Waters Associates). The SEP-P AK columns were then washed with 5 ml of H 2 0 and with 2 ml of methanol. Radioactivity remaining on the columns was <1.5% of total plasma radioactivity. The methanol wash was subsequently processed by HPLC. The HPLC eluant was sampled in fractions (every 30 s) and measured in a gamma counter. A control study in which e25I]IDex was added directly to the brain homoge nate demonstrated that no metabolism or degradation oc curred during the time necessary to perform these proce dures.
Statistical analysis
Time-activity curves were fitted using the Marquardt search algorithm minimizing the residual sum of squares. Analysis of variance (ANOV A) for the full regression was used to assess the goodness of fit. The correlation be tween muscarinic receptor concentration and tracer bind ing was determined with linear correlation analysis after proving that the data distribution was consistent with a normal distribution. Data for a given anatomical region were averaged across subjects, the resulting mean taken for computing the correlation coefficient. p values of <0.05 were considered to be statistically significant. Figure 1 shows the brain activity distribution 7 -8 h after intravenous injection of 5 mCi e 2 3l]IDex and [1231]ILev, respectively. The region-of-interest tem plates used for quantitative analysis are shown on the [1231]ILev images. e 2 31]IDex accumulates pre dominantly in frontal, temporal, parietal, and occip ital cortex as well as in neostriatum. e 2 31]IDex ac tivity in cerebellum, thalamus, and white matter is relatively low. Compared to e 2 31]IDex, brain activ ity after injection of [1 2 31]ILev is considerably re duced and homogeneous throughout the brain with out preferential localization in any region. Cardio vascular, neurological, or cognitive side effects after [1 231]IDex or [1 2 31]ILev injection were not ob served. Figure 2 shows representative kinetics of [1 2 31] _ IDe x and e 2 31]ILev. Data were analyzed using re gion-of-interest templates shown in Fig. 1. A con tinuous increase of [1 2 3I]IDex activity over 7-12 h and a subsequent plateau are common characteris tics of neostriatum, neocortex, and thalamus. Initial cerebellar [1 2 31]IDex activity is similar to that in other regions, but decreases thereafter exponen tially according to Eq. 1 (t in min): ) is identical in all brain regions. It de creases immediately after the initial peak exponentially. The best fit is obtained by using a biexponential term. Interestingly, cerebellar C231]IDex activity stays permanently at a higher level than C231]ILev activity in any brain region, suggesting the presence of muscarinic receptors in cerebellum. For abbreviations see the text.
RESULTS
The half-life of the fast component is 17 min and that of the slow component is 20.1 h. r2 for the full regression is 0.950 (ANOY A).
In contrast to e23I]IDex, the kinetics of e231]ILev derived from any brain region are indistinguishable and decline exponentially after the initial peak. The decline is described by Eq. 2 (t in min):
(2)
where the half-life of the fast component is 2.1 min and that of the slow component is 2.6 h. ? for the full regression is 0.970 (ANOY A). The improve ment of the parameter estimates compared with a monoexponential fit was significant (p < 0.006 for Eq. 1 and <0.005 for Eq. 2). Interestingly, e231]IDex activity in cerebellum, a region previously taken to measure nonspecific binding of muscarinic receptor ligands, is two times higher than [123I]ILev activity in cerebellum, neo cortex, neostriatum, and thalamus. In the other subjects, the kinetics of [123I]IDex and e231]ILev was similar in shape but different in magnitude (variance 10--30%). The rank order of regional ac tivity between different regions was identical. Figure 3 demonstrates that [1231]IDex and e23I] ILev brain activities 10--20 min after injection are correlated. The correlation becomes weaker with time and loses significance at 1.5 h after injection (data not shown).
HPLC analysis of radioactivity extracted from rat brain 20 min after intravenous injection of e251]_ IDex showed a single peak corresponding to au thentic IDex (data not shown).
J Cereb Blood Flow Metab. Vol. 12, No.4, 1992 It is one of the assumptions in this in vivo two ligand approach to muscarinic receptors that [1231] _ ILev corresponds quantitatively to free and nonspe cifically bound [1231] IDex. This assumption is sup ported by in vitro studies in rat striatum (Laduron et aI., 1978) and in vivo mouse studies (Wilson et aI., 1989) and further strengthened by the results pre sented above. Subtraction of e231]ILev images on a pixel-by-pixel basis from matching e231]IDex im ages therefore represents specific e 2 3I]IDex binding to muscarinic receptors. Corresponding subtraction images are shown in Fig. 4 . Images represent 8-mm thick contiguous slices, parallel to the bicommis sural line, extending from the cerebellum (Fig. 4A ) to the frontoparietal cortex ( Fig. 4H ). As for total e23I]IDex binding (Fig. 1) , specific [123I]IDex bind ing is most pronounced in neocortex and neostria tum. The cerebellum does bind e 2 31]IDex specifi cally. The mesial parts of the temporal lobe ( Fig. 4B and C) bind less compared with the lateral temporal areas. Specific e231]IDex binding in thalamus ( Fig.  4D and E) is low. Figure 5 shows that specific e 2 31]IDex activity in various regions of the brain 7-8 h after e 2 31]IDex injection correlates with muscarinic receptor con centrations in matched areas as measured in vitro (Cortes et aI., 1987) . The correlation is statistically significant (p < 0.001). Interestingly, the correlation holds true within neocortical regions (see Fig. 5 ; r = 0.83, n = 4, p < 0.05, regression line not shown). In contrast to [123I]IDex, there was no such corre lation for e231]ILev activity (r = 0. 06, n = 32, graph not shown). Cortical blood flow and e 2 3I]IDex and [1 2 3I]ILev activity were measured in one subject. A sagittal reconstruction of specific [1 2 3I]IDex binding and the matching blood flow image is shown in Fig. 6A and B, respectively. The distribution of [123I]IDex bind ing does not match the distribution of blood flow. Areas with maximum blood flow, such as cerebel lum and thalamus, show the lowest [1 2 3I]IDex bind ing. Neocortical areas with maximum e 2 3I]IDex ac tivity (regions of interest 3 and 12-16) are perfused to the same extent as are areas with low e23I]IDex binding (regions of interest 1 and 7-9). The occipital pole, although well perfused, does not show signif icant e23I]IDex binding. Quantitative analysis on a region-by-region basis (Fig. 6C) demonstrates the absence of a correlation between e23I]IDex activity and blood flow in neocortical areas. All the other three [1 2 31]IDex scans showed the same anteropos terior cortical pattern as the one shown in Fig. 6A .
DISCUSSION
This study describes a new approach to quantita tive SPECT imaging of muscarinic receptors in hu man brain based on the use of [1 2 31]IDex, a potent receptor antagonist, and its pharmacologically inac tive enantiomer, e23I]ILev.
A major finding is that e 2 31]IDex meets criteria for specific binding to muscarinic receptors in hu mans in vivo. [1 2 31]IDex accumulated in brain tissue FIG. 5. Regional [1231] IDex activity related to muscarinic acetylcholine receptor (mAChR) concentrations. Regional [1231]IDex activity corre lates significantly with muscarinic receptor concentrations as mea sured in vitro (Cortes et ai., 1987) . and correlated at equilibrium significantly with muscarinic receptor concentrations from human brain tissue derived in vitro. In addition, [123I]IDex binding proved to be stereospecific: [1231] ILev ac tivity declined immediately after the injection peak and showed no correlation with receptor density. The data are consistent with in vitro studies that showed a 1,000-fold lower affinity of levetimide for muscarinic receptors when compared with dexetim ide (Laduron et aI., 1978) .
With lipophilic tracers such as IDex, which have a high brain extraction, it is necessary to separate parameters indicating delivery of the tracer (re gional blood flow and diffusion across the blood brain barrier) from parameters reflecting receptor availability. The correlation between [1231]IDex ac tivity and muscarinic receptor concentration sug gests that accumulation of the ligand is mainly re ceptor driven and not predominantly a function of blood flow or diffusion. In addition, cerebral blood flow, measured with 99ffiTc-HMPAO, and [123I]IDex activity were not correlated.
The use of e231]ILev to measure nonspecific ac cumulation of e 2 3I]IDex offers certain advantages. In the case of muscarinic receptors, one cannot use competitive blockade by large doses of other antag onists (such as atropine) or agonists because of their pharmacological effects. Although the density of muscarinic receptors in cerebellum is relatively small (Cortes et aI., 1987) , their number is high enough to cause a significant overestimation of non specific binding: e23I]lDex activity in cerebellum J Cereb Blood Flow Metab, Vol. 12, No. 4, 1992 1000 was two times higher than [1231]ILev activity in any brain region. A similar approach to muscarinic cholinergic receptors has recently been reported us ing 3-quinuclidinyl-4-e25I]iodobenzilate in vitro and in vivo in rats (Gibson et aI., 1989) . It was assumed that the physicochemical properties of the (R)-and (S)-isomers are similar but the (S)-isomer will ex hibit minimal receptor-specific interactions. In con trast to the (S)-isomer of 3-quinuclidinyl-4-[1251]iodobenzilate, which has a 100-fold lower affinity to muscarinic receptors as compared with the (R)-isomer in vitro (Meyerhoffer, 1972) but only a 3-fold lower affinity for muscarinic receptors in vivo (Gibson et aI. , 1989) , levetimide has a > 1 ,OOO-foid lower affinity for muscarinic receptors in vitro than dexetimide (Laduron et aI., 1978) and does not preferentially accumulate in any brain structure in humans in vivo, as shown in the present study.
An important advantage of our approach is that 123I-Iabeled ligands permit data acquisition over a longer period of time than IIC-labeled ligands. Be tween 1 and 2 h after injection, the ratio of tracer activity in neostriatum to cerebellum, taken as in dicator of specific binding, is 1.4 to 2 for [1 2 31]IDex and IIC-Iabeled ligands such as [N-llC-methyl] scopolamine (Koeppe et aI. , 1986 (Koeppe et aI. , , 1987 Frey et aI., 1987) and [N-lIC-methyl]-benztropine (Dewey et aI., 1990) . At 8 h, however, this ratio increases to 4 using e23I]IDex. Such late measurements are not feasible with IIC owing to its short physical half life. Increased contrast between receptor-rich and 569 There is no apparent correlation. For other abbreviations see the text.
-2OOO +-�-r----r-�-r� �--�'-� �--� ��-' o receptor-poor regions offers an improvement in ac curacy of anatomical and kinetic analyses. e23I]IDex was found to bind in neostriatum and neocortex where the M 1 receptor subtype predom inates, as well as in thalamus and cerebellum com prising mainly M2 receptor subtypes (Cortes et aI., 1987) . It is therefore likely that [123I]IDex binds to 2 4 6 8 10 12 14 16
cortical regions several receptor subtypes in vivo. The findings con cur with in vitro studies demonstrating a similar af finity of dexetimide in neuroblastoma cells express ing the MI subtype, as well as heart cells having the M2 subtype (Waelbroeck et aI., 1989) . Because muscarinic receptor subtypes act via different sec ond messenger systems (Christie and North, 1988) , the nature of acetylcholine action on cholinergic synapses is determined by the receptor subtype. Ml muscarinic receptors use the phosphatidylinositol pathway, whereas the M2 muscarinic receptors probably operate through the adenyl cyclase sys tem. At the present time, subtype-selective musca rinic receptors ligands for in vivo use in humans are not available. However, focusing on basal ganglia, amygdala, and hippocampus, where Ml muscarinic receptors predominate, and on diencephalon, basal forebrain, and cerebellum with predominance of M2 muscarinic receptors (Cortes et al., 1987) would still allow a subtype-specific approach.
e 23 I]IDex is an attractive ligand owing to its high ratio of specific to nonspecific binding at late time points. The correspondence between in vivo bind ing and known muscarinic receptor concentrations and the existence and applicability of its enantio mer, [ ,23 I]ILev, also support the utility of this tracer.
